Original Article

Role of Serum PSA in Diagnosis of Prostate Cancer with Histopathological Correlation and Predictive Value of Serum PSA in Early Detection of Prostate Cancer

Authors

Avinash Parshuram Dhok¹, Amol Madanlal Lahoti², Sandeep Dhote³, Abhijit K Taori⁴, Sarang Ingole⁵, Prashant N. Mudaliar⁶, Vikrant Bhende⁷, Nihar Umakant Chandak⁸

¹Professor & Head, Department of Radiodiagnosis, NKP SIMS and Lata Mangeshkar Hospital, Nagpur
²JR III, Department of Radiodiagnosis, NKP SIMS and LMH
³Lecturer, Department of Radiodiagnosis, NKP SIMS and Lata Mangeshkar Hospital, Nagpur
⁴Assistant Lecturer, Department of Radiodiagnosis, NKP SIMS and Lata Mangeshkar Hospital, Nagpur
⁵Senior resident, Saifee Hospital, Mumbai
⁶JR II, Department of Radiodiagnosis, NKP SIMS and Lata Mangeshkar Hospital, Nagpur
⁷JR I, Department of Radiodiagnosis, NKP SIMS and Lata Mangeshkar Hospital, Nagpur
⁸Department of Surgery, NKP SIMS and Lata Mangeshkar Hospital, Nagpur

Corresponding Author

Amol Madanlal Lahoti

Department of radio-diagnosis, NKP Salve Institute of Medical Sciences and Lata Mangeshkar Hospital
Digdoh Hill, Hingna, Nagpur 440017
Phone no- +919404455075
Email: amollahoti_203@yahoo.co.in, amollahoti20031987@gmail.com

Abstract

Prostate cancer is second leading cause of death in cancer related mortality after lung cancer i.e. mortality of prostate cancer is 6.6% and that of lung cancer is 23.6%. But 5 year prevalence of prostate cancer is highest i.e. 25.5. So Prostate cancer (PC) is an important medical and socio-economical problem due to its increasing incidence among the male population and it is becoming an enormous health care burden and its early diagnosis is crucial for a successful treatment which ultimately will prolong and improve the quality of life. Widespread use of serum prostate specific antigen (PSA) level screening has dramatically increased the diagnosis of even small, early-stage prostate cancer lesions.

Aims: Role of serum PSA level in diagnosis of prostate cancer with its histopathological correlation.

Methods and Material: The study is a diagnostic cross-sectional study and Patients were informed about the nature and objective of the study and written informed consent was taken before recruiting them into the study after approval of the Institutional Ethics Committee.

Results: 1) Use of serum prostate specific antigen (PSA) level measurement increases the diagnostic accuracy of even small, early-stage prostate cancer lesions.
2) PSA level is a strong indicator of stage and prognosis.
Conclusions: The findings of study indicates that serial measurement of serum PSA level help in diagnosis of even small and early-stage prostate cancer. PSA level is indirect indicator of stage and prognosis of prostate cancer. Screening is advised in male population older than 50 years.

Keywords: prostate specific antigen, Prostate cancer, early diagnosis, screening

Key Messages: Screening male adults over 50 years of age with Prostatic specific antigen (PSA) can help diagnose prostate cancer early so as to prevent complications arising out of late diagnosis. Serum PSA is cost effective, easily available and non-invasive screening test.

Introduction
Prostate cancer is disease of elderly male population. Its incidence has been increase in last few years. It is second leading cause of death in cancer related mortality after lung cancer Prostate cancer (PC) is an important medical and socio-economical problem due to its increasing incidence among the male population and It is becoming an enormous health care burden and its early diagnosis is crucial for a successful treatment which ultimately will prolong and improve the quality of life.

Prostate cancer is one of the most common cancer in men and is responsible for 19% of all newly diagnosed male cancers. Serum prostate specific antigen (PSA) screening is helpful in early diagnosis and staging of prostate cancer. Prostate cancer (PC) is the most common in men above the age of 50 years, more than 60% of cases occurring in men over 70 years of age.

Incidence rates rise steeply with age. Ninety percent of malignant prostate tumours are adenocarcinoma. The aetiology of PC remains controversial, although several risk factors have been identified. The most important risk factors include increasing Age, family History and ethnicity (male from black African, African American or black Caribbean ancestry). Men with prostate cancer may remain asymptomatic or may present with problems with urination, such as frequent urination, hematuria, urgency, burning, micturition, inability to urinate or control urine flow, weight loss, decreased appetite, back pain, etc. although these symptoms are not specific to prostate cancer.

PSA is a protein produced by normal prostate cells. This enzyme participates in the dissolution of the seminal fluid coagulum and plays an important role in fertility. The highest concentration of PSA is found in the seminal fluid, where it was first discovered. The half-life of PSA is about 2.2 to 3.2 days. Because of its relatively long half-life, a minimum of 2-3 weeks is required for the serum PSA to reach its nadir following radical prostatectomy, when it should be undetectable. Widespread use of serum prostate specific antigen (PSA) level screening has dramatically increased the diagnosis of even small, early-stage prostate cancer lesions. PSA is the product of prostatic epithelium and is normally secreted in the semen. It is an androgen regulated serine protease whose function is to cleave and liquefy the seminal coagulum formed after ejaculation. In normal male, only minute amount of PSA circulate in serum.

PSA Level test
PSA level is a strong indicator of stage and prognosis and is helpful in monitoring response to therapy for prostatic lesion. PSA levels are elevated in prostate cancer but they may also be elevated in prostatitis and benign prostatic hyperplasia. The normal serum PSA level is under 4 ng/ml. A PSA level of 4 to 10 ng/ml is considered borderline for abnormality; 20% of such patients have prostate cancer. Most patients with a PSA greater than 10 ng/l have prostate cancer. In addition to diagnosis, PSA level is also correlated with pathologic stage. Several refinements to the standard PSA measurement have been introduced in order to increase the accuracy of prostate-specific cancer identification. These refinements include PSA density (PSA divided by the prostate volume), PSA transition zone density (PSA divided by the volume of the
transition zone), free to total PSA ratio (the fraction of unbound serum PSA), and PSA velocity (the rate of change in PSA over time). In last few decades incidence of prostate cancer has been increased, so it is an important medical and socio-economical problem due to its increasing incidence and it is becoming an enormous health care burden.

Subjects and Methods
After approval of the “Institutional Ethics Committee” cross-sectional study done to evaluate and compare the role of PSA in screening and diagnosis of prostate cancer with MRI prostate. Patients were informed about the nature and objective of the study and written informed consent was taken before recruiting them into the study. The source of data for the study were patients with prostatic pathologies presenting to the Radiology and Surgery OPD at tertiary care hospital/ our institute.

USG machine - Mylab 50 and my lab 40, corevision.
All the laboratory/pathology tests were carried out in a single setting at our institute.

Methodology
Relevant history of illness and significant clinical findings of all patients were recorded. Previous investigations were reviewed. Serum PSA level assessed and post-operative or post-biopsy follow up was taken.

Inclusion Criteria
All patients with suspicion of prostate pathologies (lower urinary tract symptoms like increased frequency of micturition, hesitancy, urgency & hard /enlarged prostate on digital rectal examination), enlarged prostate on ultrasound abdomen and/or PSA levels (>4ng/ml).

Exclusion Criteria
Any previous biopsy done, less than 6 weeks before.

Statistical Analysis
Continuous variables were summarized as mean and standard deviations whereas nominal /categorical variables as proportions (%). A Chi-square test was used for analysis of nominal/categorical variables. Z test for difference between two proportions was used for comparison of nominal/categorical variables. Unpaired —t test and ANOVA test were used for continuous variables. Diagnostic accuracy of PSA and MRI was assessed by means of sensitivity, specificity, PPV and NPV.

P value < 0.05 was taken as significant. Medcalc 14.0.0 version was used for all statistical calculations.

Results
Maximum patients were in age group of 61-70 years.
Mean age in the benign category (patients with histopathologically, no cancer) was 60 years, while mean age in the malignant category (patients with histopathologically, cancer) was 69 years.

Table 2- Distribution of patients as per zonal distributions of lesions on USG

| Zone                  | No. of patients (%) |
|-----------------------|---------------------|
| Central               | 5 (7.57)            |
| Peripheral            | 28 (42.4)           |
| Transition            | 31 (46.9)           |
| Peripheral and transition | 2 (3.03)         |
| Total                 | 66                  |

Table 3 shows the distribution of patients as per zonal distribution of lesions on USG. Maximum 47 %lesions in were in transition zone, followed by 43% in peripheral zone. There were 5 (7.57%) in the central and 2 (3.03%) in the peripheral and transition zone.
ROC analysis – Prostate Specific Antigen (PSA) with Histopathological finding

| PSA categories | Histopathological finding | Total |
|----------------|---------------------------|-------|
|                | Benign | Malignant |       |
| <= 4           | 4      | 0         | 4     |
| 4.1 – 10       | 6      | 9         | 15    |
| > 10.1         | 15     | 32        | 47    |
| Total          | 25     | 41        | 66    |

Chi-square: 7.2991; P-value: 0.026 (Significant)

Those patients who were having higher PSA values but benign disease were either gross prostatomegaly or serum PSA studied after prostate manipulation (per rectal clinical examination or TRUS) or patients having prostatitis. In the literature it is given that not only malignant lesions but benign prostatic hyperplasia, manipulation, biopsy, per rectal examinations.

**Discussion**

Prostate is an organ in which various focal or diffuse, benign or malignant primary pathology/lesion can be found. Use of serial serum prostate specific antigen (PSA) level measurement increases the diagnosis prostate cancer lesions. Serum PSA level is strongly correlated with stage and prognosis of prostate cancer. There is strong controversy in the literature whether serum PSA should be done for screening for prostate cancer early diagnosis so as to prevent complications associated with the late diagnosis. However in our study we found that as serum PSA study is non-invasive, cost effective and easily available test and should be done routinely as a screening test for prostate cancer.

**Physiological Considerations**

The main role of the prostate is to produce fluid, which accounts for up to 30% of the semen volume. It aids sperm motility and provides nourishment. Prostatic fluid is a thin, milky alkaline liquid containing citric acid, calcium, zinc, acid phosphatase and fibrinolysin as well as PSA. PSA helps to keep the semen in its liquid form. It is an enzyme in the form of a glycoprotein produced primarily by cells lining the acini and ducts of the prostate gland.

PSA is considered as the most useful tumor marker for diagnosis, staging and monitoring of prostate cancer. It correlates well with advanced clinical and pathological stages in most cases, but due to low specificity it cannot accurately stage an individual patient as there is large overlap between different tumor stages. Also, other benign causes such as benign prostatic hyperplasia and prostatitis can cause elevated PSA levels.
PSA \(^{3,4,5,6}\) is a protein produced by normal prostate cells. This enzyme participates in the dissolution of the seminal fluid coagulum and plays an important role in fertility. The highest concentration of PSA is found in the seminal fluid, where it was first discovered. The half-life of PSA is about 2.2 to 3.2 days. Some PSA escapes the prostate and can be found in the serum. PSA was first identified and purified in 1970s. However, its widespread use in clinical urology did not occur until 1980s. PSA levels are elevated in prostate cancer but they may also be elevated in prostatitis and benign prostatic hyperplasia. The normal serum PSA level is under 4 ng/ml. A PSA level of 4 to 10 ng/ml is considered borderline for abnormality; 20% of such patients have prostate cancer. Most patients with a PSA greater than 10 ng/l have prostate cancer. In addition to diagnosis, PSA level is also correlated with pathologic stage. In a Mayo Clinic study of 945 radical prostatectomies, the percentage of patients with extra prostatic disease was related to PSA level.

| PSA (ng/ml) | <2 | 2-10 | 10-25 | 25-50 | >50 |
|------------|----|------|-------|-------|-----|
| Extra-prostatic Disease | 30% | 47% | 67% | 83% | 93% |

Recent research studies however has criticised its effectiveness in detecting cancer through PSA. It has been shown that many men may harbour prostate cancer despite low levels of PSA. Several refinements to the standard PSA measurement have been introduced to try and increase the accuracy of prostate-specific cancer identification. These refinements include PSA density (PSA divided by the prostate volume), PSA transition zone density (PSA divided by the volume of the transition zone), free to total PSA ratio (the fraction of unbound serum PSA), and PSA velocity (the rate of change in PSA over time). These new refinements have not yet entered into widespread clinical practice.

T. Rieden (2012) et al\(^7\) prospectively evaluated 56 patients (mean age 67±5,4 years) with elevated serum prostate specific antigen (PSA) levels (4.0>ng/mL), who were referred to MRI studies before prostate biopsy. All the patients underwent 12-core prostate biopsy which was he reference standard. Mean value of PSA level in 56 patients was 12,8±7,2 ng/mL. In 50 patients (89,3% of patients) 68 sites of suspected cancer were found. 6 patients (10,7% of patients) were diagnosed with benign prostatic hyperplasia (BPH). 33 sites (48,5%) were localized in transition zone (TZ), 23 (33,9%) in peripheral zone (PZ), 12 (17,6%) in both zones. Histologically prostate cancer was proven in 39 of 50 patients (78%) with suspected cancer, mean PSA level 13,8±8,6 ng/mL. The median Gleason score was 6,6. Cancer cells were found in 54 of 68 sites (79,4%): 23 sites (42,6%) were localized in TZ, 19 (35,2%) - in PZ, 12 (22,2%) - in both zones Among 14 of false-positive sites 10 were localized in transition and 4 in peripheral zone; in all of them histological pattern of BHP was found. Furthermore, in 12 sites of 14 false positives (8 - TZ, 4 - PZ) prostatic intraepithelial neoplasia (PIN) was diagnosed (8 of 11 patients with non-proven cancer, mean PSA level 10,5±4,2 ng/mL). In some of them focal area suspicious for neoplastic lesion on ADC map was very small, so it was difficult to measure ADC value correctly because of insufficient ROI square. ADC values were measured in 60 of 68 sites suspected for prostate cancer (88,2%);its mean value was 0,81x10-3 mm²/s (0,42x10-3 mm²/s - 1,2x10-3 mm²/s). For 14 non cancer sites mean ADC value was 1,18 x 10-3 mm²/s (0,79x10-3 mm²/s - 1,5x10-3 mm²/s). As today PIN is considered a pre-malignant lesion DWI with either separate or fused images showed 100% sensitivity, 75% specificity and 96,4% accuracy. Fusion images didn't significantly improve the performance of standard MRI+DWI, but they were helpful in more precise localization of the cancer sites which were not clearly visible on T2WI alone Pre-biopsy DWI with high b-value improves diagnostic performance of MRI in prostate cancer detection and localization with higher accuracy in peripheral zone; it can show additional sites to be carefully histologically examined. Fusion T2WI+DWI imaging is helpful.
for better localization of suspected tumor sites. PSA remains the best and most widely used tumor marker in urology today.

**PSA modalities**
Modalities to enhance PSA usability are PSA velocity, PSA density, age-specific PSA and free/total PSA ratio.

**PSA velocity**
Is defined as the change of PSA value over time; it enhanced the specificity for prostate cancer detection from 42% to 96%, compared to a single reading of PSA. In another recent large scale study which involved 4,272 patients and which extended over a 10 year period, men with prostate cancer were found to have significantly greater PSA velocity than those without cancer (0.39 versus 0.03). PSA velocity as a predictor of tumour stage and grade remains controversial. Another important and established role of PSA velocity is the follow up of patients with prostate cancer who are either on active surveillance strategy, hormone manipulation or post radical treatment.

**PSA density**
This is defined as the serum PSA level divided by the volume of the prostate. It allows adjustments for the PSA component that arise from benign prostatic hypertrophy which arises mainly in the transitional zone. The clinical use of PSA density has been debated. In a study done by Freedland et al the additional time and effort required to calculate PSA density was not justified by the minimal improvement in predicting tumour stage, surgical margin and biochemical recurrence after radical prostatectomy. However, more recent studies have shown that PSA density may add additional prognostic value to predict cancer progression. Tosoian et al, from John Hopkins Hospital, considered PSA density as an important criterion for patients who opted for an active surveillance strategy.

**Role of free/total PSA**
This parameter has emerged after the discovery that PSA exists in a bound form with other proteins and free (unbound) form that can be detected with immunoassays. Stenman et al were the first to establish that men with prostate cancer had more complexed PSA (cPSA) than free PSA (fPSA), in contrast to men with benign prostatic hypertrophy, suggesting that the assay of the complex and its proportion to total PSA immune reactivity can be used to differentiate between PSA elevations caused by benign and malignant prostatic disease. A clinical study done in Egypt showed that men with prostate cancer and a lower free/total PSA ratio had higher Gleason scores than those with higher free/total PSA.

PSA testing is minimally invasive, simple and safe. Serum PSA elevation may indicate the presence of prostatic disease (including prostate cancer, benign prostatic hypertrophy, urinary retention and prostatitis) or result from prostate manipulation such as transrectal biopsy and prostatic massage. Elevation of PSA above 4ng/mL carries a 22% probability of prostate cancer and a further increase above 10ng/mL raises the cancer risk to 63%.

**Conclusion**
Present study indicates that measurement of serum PSA level in patients with strong clinical suspicion of Prostate pathologies increases the diagnostic accuracy of even small, early-stage prostate cancer lesions. PSA level is correlated with stage and prognosis of prostate cancer. Due to increasing incidence of prostate cancer, prostate cancer can be picked and further imaging studies can be done in patients with elevated PSA. Biopsy is advised for suspicious lesion.

**Source of Support:** Nil

**Conflict of Interest:** None declared.

**References**
1. Aaleshwaran KK, Mittal BR, Harisankar CN, Bhattacharya A, Singh SK, Mandal AK. Predictive value of serum prostate specific antigen in detecting bone metastasis in prostate cancer patients using bone scintigraphy. Indian J Nucl Med. 2012 Apr;81-84
2. Polascik TJ, Oesterling JE, Partin AW. Prostate specific antigen: a decade of discovery--what we have learned and where we are going. J Urol. 1999 Aug;162(2):293-306
3. Scardino PT, Weaver R, M'Liss AH. Early detection of prostate cancer. Human pathology. 1992 Mar 1;23(3):211-22.
4. Kleer E, Larson-Keller JJ, Zincke H, Oesterling JE. Ability of preoperative serum prostatespecific antigen value to predict pathologic stage and DNA ploidy Influence of clinical stage and tumor grade. Urology. 1993 Mar 31;41(3):207-16
5. Andriole GL, Crawford ED, Grubb III RL, Buys SS, Chia D, Church TR, Fouad MN, Gelmann EP, Kvale PA, Reding DJ, Weissfeld JL. Mortality results from a randomized prostate-cancer screening trial. New England Journal of Medicine. 2009 Mar 26;360(13):1310-9
6. Heidenreich A, Aus G, Bolla M, Joniau S, Mateueu V, Schmid HP, and Zatonni F. EUA guidelines on prostate cancer. European Urology 2008; 53(2): 260-72
7. Rieden T. Diffusion-weighted MRI in prostate cancer detection: evaluation of its performance with pathohistological correlation. Eur. Congress of Radiology 2012.
8. Crawford ED, Thompson IM. Controversies regarding screening for prostate cancer. BJU Int Supp. 2007: 100:5-7
9. Berger AP, Deibl M, Strasak A, et al. Large-scale study of clinical impact of PSA velocity: long-term PSA kinetics as method of differentiating men with from those without prostate cancer. Urology. 2007 Jan; 69:134-38
10. Jesberger JA, Rafie N, Duerk J, et al. Model-free parameters from dynamic contrast-enhanced-MRI: Sensitivity to EES volume fraction and bolus timing. Journal of Magnetic Resonance Imaging. 2006: 24:586-94
11. Pinsky PF, Andriole G, Crawford ED, et al. Prostate-specific antigen velocity and prostate cancer gleason grade and stage. Cancer. 2007 Apr 15:109:1689-95
12. Boccon-Gibod L, Djavan WB, Hammerer P, et al. Management of prostate-specific antigen relapse in prostate cancer: a European Consensus. Int J Clin Pract. 2004 Apr: 58:382-90
13. Brawer MK. Prostate-specific antigen: current status. CA: a cancer journal for clinicians. 1999 Sep-Oct: 49:264-81
14. Freedland SJ, Kane CJ, Presti JC, Jr., et al. Comparison of preoperative prostate specific antigen density and prostate specific antigen for predicting recurrence after radical prostatectomy: results from the search data base. The Journal of urology. 2003 Mar: 169:969-73
15. Tosoian JJ, Trock BJ, Landis P, et al. Active surveillance program for prostate cancer: an update of the Johns Hopkins experience. J Clin Oncol. 2011 Jun 1: 29:2185-90
16. Stenman UH, Leinonen J, Alfthan H, Rannikko S, Tuhkanen K, Alfthan O. A complex between prostate-specific antigen and alpha 1-antichymotrypsin is the major form of prostate-specific antigen in serum of patients with prostatic cancer: assay of the complex improves clinical sensitivity for cancer. Cancer research. 1991 Jan 1: 51:222-26
17. Elabbady AA, Khedr MM. Free/total PSA ratio can help in the prediction of high gleason score prostate cancer in men with total serum prostate specific antigen (PSA) of 3-10 ng/ml. International urology and nephrology. 2006: 38:553-57
18. Catalona WJ, Smith DS, Ratliff TL, et al. Measurement of prostate specific antigen in serum as a screening test for prostate cancer. The New England journal of medicine. 1991 Apr 25: 324:1156-61